公开(公告)号：US20230321038A1

公开(公告)日：2023-10-12

申请号：US18044024

申请日：2021-09-03

Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (AN INDIAN REGISTERD BODY INCORPORATIED UNDER THE REGN

Inventor： Srivari CHANDRASEKHAR ,  Prathama S MAINKAR ,  Chada RAJI REDDY ,  Sistla RAMAKRISHNA ,  Andugulapati SAI BALAGI ,  Kuncha MADHUSUDANA ,  Muppidi MOHAN VENKATA SUBBARAO ,  Tirunavalli SATYA KRISHNA

IPC: A61K31/404 ,  A61K31/4439 ,  A61P11/00

CPC classification number: A61K31/404 ,  A61K31/4439 ,  A61P11/00

Abstract: The present invention relates to compound of Formula 1 for use in treating IPF, by reducing collagen deposition in lungs, attenuating the fibrotic marker's expression (in IPF cell-lines Bleomycin induced rat lungs) and improving the bleomycin induced pathological changes in rat lungs, and ARDS, by reducing the cytokine storm. The invention also relates to compound of Formula 1 for use in treating various fibrotic disorders like lung injuries caused by virus or bacterial infections, cardiac, hepatic and kidney fibrosis.

公开(公告)号：US11780912B2

公开(公告)日：2023-10-10

申请号：US17333256

申请日：2021-05-28

Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA ,  JICHI MEDICAL UNIVERSITY ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION

Inventor： Ayako Kakiuchi ,  Atsuhiko Kato ,  Shuji Hayashi ,  Izumi Yanagisawa ,  Ryo Konno ,  Sachiho Netsu ,  Tadashi Sankai

IPC: A61K39/00 ,  C07K16/24 ,  A61P15/00 ,  A61P29/00 ,  A61P11/00 ,  A61K45/00 ,  A61P1/16 ,  A61K39/395 ,  A61P13/12 ,  A61P43/00 ,  A61P17/06 ,  A61P15/08 ,  C07K16/28

CPC classification number: C07K16/244 ,  A61K39/395 ,  A61K45/00 ,  A61P1/16 ,  A61P11/00 ,  A61P13/12 ,  A61P15/00 ,  A61P15/08 ,  A61P17/06 ,  A61P29/00 ,  A61P43/00 ,  C07K16/2866 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/24 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92 ,  C07K2317/94

Abstract: For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided.

公开(公告)号：US20230312580A1

公开(公告)日：2023-10-05

申请号：US18008352

申请日：2021-06-07

Applicant: MISSION THERAPEUTICS LIMITED

Inventor： Christopher Andrew LUCKHURST ,  Mark Ian KEMP ,  Paul William THOMPSON ,  Martin Lee STOCKLEY

IPC: C07D487/04 ,  C07D417/12 ,  A61P11/00 ,  A61P1/16 ,  A61P25/28 ,  A61P13/12

CPC classification number: C07D487/04 ,  A61P1/16 ,  A61P11/00 ,  A61P13/12 ,  A61P25/28 ,  C07D417/12

Abstract: The present invention relates to hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitriles with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis:.

公开(公告)号：US20230310376A1

公开(公告)日：2023-10-05

申请号：US18042170

申请日：2021-08-25

Applicant: ONO PHARMACEUTICAL CO., LTD. ,  TOHOKU UNIVERSITY

Inventor： Junken AOKI ,  Kuniyuki KANO ,  Yasuaki HASHIMOTO ,  Michiaki KADODE ,  Yuji KAWAHARA

IPC: A61K31/405 ,  A61P11/00

CPC classification number: A61K31/405 ,  A61P11/00

Abstract: A prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis is disclosed. The prophylactic and/or therapeutic agent for idiopathic interstitial pneumonia (IPF or the like) contains a compound having an LPA3 agonistic activity or a salt thereof. Examples of LPA3 agonists include compounds having a structural formulae (IA) to (IIIA) are disclosed as agonists or antagonist of EDG7 (=LPA3) receptor:

公开(公告)号：US20230310364A1

公开(公告)日：2023-10-05

申请号：US18000880

申请日：2021-07-09

Applicant: Incannex Healthcare Limited

Inventor： Mark Robert BLEACKLEY ,  Sudhanshu AGARWAL ,  Joel Bradley LATHAM

IPC: A61K31/352 ,  A61K31/433 ,  A61P11/00

CPC classification number: A61K31/352 ,  A61P11/00 ,  A61K31/433

Abstract: Compositions including Δ-9-tetrahydrocannabinol (THC) and a carbonic andydrase inhibitor and methods of using these compositions for the treatment of obstructive sleep apnoea (OSA). The treatment method also includes administering dronabinol and acetazolaminde and combinations thereof to a subject in need thereof.

公开(公告)号：US11771684B2

公开(公告)日：2023-10-03

申请号：US17477953

申请日：2021-09-17

Applicant: Centaurus Therapeutics

Inventor： Donna L. Romero ,  John M. McCall ,  Jeremy Blitzer

IPC: A61K9/00 ,  A61K39/395 ,  A61K31/44 ,  A61K31/167 ,  A61K31/416 ,  A61K31/444 ,  A61K31/496 ,  A61P9/10 ,  A61P3/06 ,  A61P3/10 ,  A61P11/00 ,  A61P35/00 ,  C07C233/65 ,  C07D213/73 ,  C07D231/56 ,  C07D401/12 ,  C07D401/14

CPC classification number: A61K31/44 ,  A61K9/0053 ,  A61K31/167 ,  A61K31/416 ,  A61K31/444 ,  A61K31/496 ,  A61K39/3955 ,  A61P3/06 ,  A61P3/10 ,  A61P9/10 ,  A61P11/00 ,  A61P35/00 ,  C07C233/65 ,  C07D213/73 ,  C07D231/56 ,  C07D401/12 ,  C07D401/14

Abstract: Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

公开(公告)号：US20230303964A1

公开(公告)日：2023-09-28

申请号：US17916421

申请日：2021-03-31

Applicant: BLIS TECHNOLOGIES LIMITED

Inventor： John David Francis Hale ,  John Robert Tagg

IPC: C12N1/20 ,  A61K31/4706 ,  A61K38/12 ,  A61K38/14 ,  A61K45/06 ,  A61P11/00 ,  A61P31/16

CPC classification number: C12N1/205 ,  A61K31/4706 ,  A61K38/12 ,  A61K38/14 ,  A61K45/06 ,  A61P11/00 ,  A61P31/16 ,  C12R2001/46

Abstract: This invention relates to methods of prophylactically or therapeutically treating viral infections particularly in the lower respiratory tract. Treatment of coronavirus infections is particularly contemplated. The invention also relates to the use of BLIS-producing Streptococcus strains, extracts and exudates thereof, and compositions containing same in the prevention, reduction, or treatment of such virus infections.

公开(公告)号：US20230303686A1

公开(公告)日：2023-09-28

申请号：US17971520

申请日：2022-10-21

Applicant: Allakos Inc.

Inventor： Christopher Robert BEBBINGTON ,  Nenad TOMASEVIC ,  Rustom FALAHATI ,  Bradford Andrew YOUNGBLOOD

IPC: C07K16/28 ,  A61P37/06 ,  A61P11/00

CPC classification number: C07K16/2803 ,  A61P37/06 ,  A61P11/00 ,  A61K2039/505

Abstract: The invention provides methods and compositions for the prevention or treatment of fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis. In particular, the invention provides methods for the prevention or treatment of fibrotic diseases and pre-fibrotic diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention or treatment fibrotic diseases such as idiopathic pulmonary fibrosis and pre-fibrotic diseases such as chronic hypersensitivity pneumonitis.

公开(公告)号：US20230301933A1

公开(公告)日：2023-09-28

申请号：US17995616

申请日：2021-04-07

Applicant: Wen Zhi LIN

Inventor： Wen Zhi LIN

IPC: A61K31/05 ,  A61K9/00 ,  A61P11/00

CPC classification number: A61K31/05 ,  A61K9/0019 ,  A61P11/00

Abstract: Described is the use of phenol for the treatment of microbially, in particular virally, induced dyspnoea in a patient, in particular a human patient, wherein the phenol is administered parenterally. The dyspnoea is in particular associated with Acute Respiratory Distress Syndrome (ARDS). The viral infection is particularly caused by a virus, chosen from the group, consisting of corona, influenza, Ebola, respiratory syncytial virus, HIV, Lassa and rhinovirus. Phenol is administered parenterally, in particular subcutaneously or intravenously.

公开(公告)号：US20230287413A1

公开(公告)日：2023-09-14

申请号：US17995722

申请日：2021-04-09

Applicant: Technische Universität München

Inventor： Stefan ENGELHARDT ,  Deepak Prabhu RAMANUJAM

IPC: C12N15/113 ,  A61P11/00 ,  A61K47/54

CPC classification number: C12N15/113 ,  A61K47/549 ,  A61P11/00 ,  C12N2310/141

Abstract: The present invention relates to a composition for use in the treatment of pulmonary fibrosis of a subject, wherein the composition comprises an inhibitor of miR-21 and a moiety that delivers said inhibitor of miR-21 to a macrophage. Further, the composition may be administered by a pulmonary administration. In particular aspects, said subject to be treated suffers from pulmonary fibrosis and further has a lung disease or disorder, wherein the lung disease or disorder may be a corona virus disease. Furthermore, the invention relates to a composition, wherein the composition comprises an inhibitor of miR-21 and a moiety that delivers said inhibitor of miR-21 to a lung macrophage.